Founder, President and CEO Peter C. Johnson, MD Dr. Johnson was educated at the University of Notre Dame and the SUNY Upstate Medical University. He completed General Surgery and Plastic Surgery residencies at Case-Western Reserve University and the University of Pittsburgh, respectively. He took a postdoctoral fellowship in thrombosis/platelet biology at Harvard University. Dr. Johnson practiced reconstructive surgery for ten years on the University of Pittsburgh faculty where he founded and was the first President of the Pittsburgh Tissue Engineering Initiative, after which he co-founded and was CEO of TissueInformatics.Inc. Prior to founding Scintellix, he served as Chief Medical Officer, Executive Vice President of Life Sciences and Chief Business Officer of Icoria, Inc. Dr. Johnson is a past Chairperson of the Plastic Surgery Research Council, President of the Pennsylvania Biotechnology Association (PaBiotech), the Tissue Engineering Society, International (now TERMIS) and is presently the Co-Editor-in-Chief of the three-part Journal, Tissue Engineering. He serves on the Board of Trustees of the Pittsburgh Tissue Engineering Initiative, Microscience Group and the University of North Carolina Medical Foundation. He also serves as the National Chairman of the University of North Carolina at Chapel Hill School of Medicine Medical Excellence Fund. Scintellix Associates Complex problems often demand a wide variety of skills for their solution. At Scintellix, we believe in the concept of Minimal Essential Teams, functioning cohesively to bring closure to complex problems. This is made possible by the Scintellix Associates, a network of highly trusted colleagues selected for their knowledge, motivation, capacity to work with one another and with clients. Examples of services that the Scintellix Associates provide: 1. Strategic planning concurrent with an understanding of technology and human resource issues. 2. Planning for financing that must be underpinned by a clear presentation of technology and marketing issues. 3. Determination of optimal board and management leadership relative to the financial and cultural circumstances in the company. Recruitment of these leaders as needed. 4. Planning for technology transfer steps, including intellectual property issues and their interface with financing strategy. 5. Close primary interface marketing with the medical practitioners and life scientists. 6. Ensuring communication between key technology development teams during periods of corporate transition and turmoil. 7. Creating clarity between technology development teams and management and sales and marketing to precisely identify product development status before external communication. 8. Planning for and executing business development activities, including sales, licensing and merger and acquisition activities. 9. Regulatory and reimbursement planning. 10. Interim management. 11. Business development and licensing. Specific Technology Domains of Expertise Include:
Scintellix Partners Scintellix works with partner organizations to serve our clients' unique needs. Some of our trusted partners include: Biosolutions Services, LLC, Boston, MA - Business development and technology development services in biomedicine. Fuentek, LLC - Intellectual property assessment and management in cross-cutting technology sectors. Glexel Consulting, Kalamazoo, MI - Providing world-class project management support to design, develop, and implement business processes that meet or exceed business objectives. Innovalyst, LLC - A life sciences consulting company. Catalyzes the growth of early-stage and established companies through the development and commercialization of innovations. Personalized Medicine Partners, LLC, Raleigh, NC - Providing pharmaceutical technology assessment and business development services in the personalized medicine sector. Smart Consulting, LLC, Mebane, NC - Medical device regulatory consulting. Contact: 919-844-0343 info@scintellix.com |
 |
| |
 |
| |
 |
| |
 |
Our People
